99mTc-TRODAT-1 SPECT as a potential neuroimaging biomarker in patients with restless legs syndrome

Clinical Nuclear Medicine

Volumn 41, Issue 1, 2016, Pages e14-e17

  Lin, Chun Chieh ^a   Fan, Yu Ming ^b,c   Lin, Guan Yu ^a   Yang, Fu Chi ^a   Cheng, Chun An ^a   Lu, Kuo Cheng ^b   Lin, Jen Cheng ^d   Lee, Jiunn Tay ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b CARDINAL TIEN HOSPITAL   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

99mTc TRODAT 1; dopamine transporter; restless legs syndrome; SPECT

Indexed keywords

DOPAMINE TRANSPORTER; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; BIOLOGICAL MARKER; DOPAMINE; TECHNETIUM COMPLEX; TECHNETIUM TC 99M TRODAT-1; TROPANE DERIVATIVE;

ADULT; ARTICLE; BASAL GANGLION; CASE CONTROL STUDY; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; NEUROIMAGING; PROSPECTIVE STUDY; PUTAMEN; RADIOACTIVITY; RESTLESS LEGS SYNDROME; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BRAIN; CLINICAL TRIAL; METABOLISM; PROCEDURES; SCINTISCANNING;

BIOMARKERS; BRAIN; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROIMAGING; ORGANOTECHNETIUM COMPOUNDS; RESTLESS LEGS SYNDROME; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 84951081124     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000000916     Document Type: Article

References (26)

1. Allen RP, Walters AS, Montplaisir J, Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005; 165: 1286-1292
2. Innes KE, Selfe TK, Agarwal P,. Prevalence of restless legs syndrome in North American and Western European populations: a systematic review. Sleep Med. 2011; 12: 623-634
3. Schapira AH,. Restless legs syndrome: an update on treatment options. Drugs. 2004; 64: 149-158
4. Becker PM, Jamieson AO, Brown WD,. Dopaminergic agents in restless legs syndrome and periodic limb movements of sleep: response and complications of extended treatment in 49 cases. Sleep. 1993; 16: 713-716
5. Montplaisir J, Nicolas A, Denesle R, Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology. 1999; 52: 938-943
6. Ondo WG,. Restless legs syndrome: pathophysiology and treatment. Curr Treat Options Neurol. 2014; 16: 317
7. Dowling P, Klinker F, Stadelmann C, Dopamine D3 receptor specifically modulates motor and sensory symptoms in iron-deficient mice. J Neurosci. 2011; 31: 70-77
8. Trenkwalder C, Walters AS, Hening WA, Positron emission tomographic studies in restless legs syndrome. Mov Disord. 1999; 14: 141-145
9. Michaud M, Soucy JP, Chabli A, SPECT imaging of striatal pre-And postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol. 2002; 249: 164-170
10. Marshall V, Grosset D,. Role of dopamine transporter imaging in routine clinical practice. Mov Disord. 2003; 18: 1415-1423
11. Kung HF, Kung MP, Choi SR,. Radiopharmaceuticals for single-photon emission computed tomography brain imaging. Semin Nucl Med. 2003; 33: 2-13
12. Earley CJ, Kuwabara H, Wong DF, The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome. Sleep. 2011; 34: 341-347
13. Kung HF, Kim HJ, Kung MP, Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. Eur J Nucl Med. 1996; 23: 1527-1530
14. Lu CS, Weng YH, Chen MC, 99mTc-TRODAT-1 imaging of multiple system atrophy. J Nucl Med. 2004; 45: 49-55
15. Bao SY, Wu JC, Luo WF, Imaging of dopamine transporters with technetium-99m TRODAT-1 and single photon emission computed tomography. J Neuroimaging. 2000; 10: 200-203
16. Pedroso JL, Braga-Neto P, Felicio AC, Sleep disorders in Machado-Joseph disease: a dopamine transporter imaging study. J Neurol Sci. 2013; 324: 90-93
17. Montplaisir J, Godbout R, Poirier G, Restless legs syndrome and periodic movements in sleep: physiopathology and treatment with l-dopa. Clin Neuropharmacol. 1986; 9: 456-463
18. Turjanski N, Lees AJ, Brooks DJ,. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology. 1999; 52: 932-937
19. Connor JR, Wang XS, Allen RP, Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain. 2009; 132: 2403-2412
20. Savva E, Schnorf H, Burkhard PR,. Restless legs syndrome: an early manifestation of Huntington's disease? Acta Neurol Scand. 2009; 119: 274-276
21. Gasser T,. Advances in the genetics of movement disorders: implications for molecular diagnosis. J Neurol. 1997; 244: 341-348
22. Earley CJ, P BB, Horska A, MRI-determined regional brain iron concentrations in early-And late-onset restless legs syndrome. Sleep Med. 2006; 7: 458-461
23. Cervenka S, Palhagen SE, Comley RA, Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain. 2006; 129: 2017-2028
24. Cavagnolli DA, Esteves AM, Castiglione ML, Dopamine transporter shown by SPECT in patients with periodic leg movement after acute physical exercise. Med Sci Sports Exerc. 2013; 45: 224-229
25. Kim KW, Jhoo JH, Lee SB, Increased striatal dopamine transporter density in moderately severe old restless legs syndrome patients. Eur J Neurol. 2012; 19: 1213-1218
26. Eisensehr I, Ehrenberg BL, Noachtar S,. Different sleep characteristics in restless legs syndrome and periodic limb movement disorder. Sleep Med. 2003; 4: 147-152